Outcome of Sublingual Immunotherapy in Allergic Rhinitis

Das, Debajyoti; Sit, Santanu; Khaowas, Ajoy Kumar; Das, Chhanda; Mukherjee, Dwaipayan

doi:10.1007/s12070-021-02465-4

Cited by 2 publications

(1 citation statement)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another independent study measuring SNOT-20 score after SLIT treatment in AR reported a reduction in AR symptoms and improvement in QOL of AR patients ( 111 ). AIT is proven to be a safe treatment for pediatrics AR.…”

Section: Treatment Of Allergic Rhinitismentioning

confidence: 99%

Allergic Rhinitis: A Clinical and Pathophysiological Overview

et al. 2022

View full text Add to dashboard Cite

Allergic rhinitis (AR) represents a global health concern where it affects approximately 400 million people worldwide. The prevalence of AR has increased over the years along with increased urbanization and environmental pollutants thought to be some of the leading causes of the disease. Understanding the pathophysiology of AR is crucial in the development of novel therapies to treat this incurable disease that often comorbids with other airway diseases. Hence in this mini review, we summarize the well-established yet vital aspects of AR. These include the epidemiology, clinical and laboratory diagnostic criteria, AR in pediatrics, pathophysiology of AR, Th2 responses in the disease, as well as pharmacological and immunomodulating therapies for AR patients.

show abstract

Section: Treatment Of Allergic Rhinitismentioning

confidence: 99%

Allergic Rhinitis: A Clinical and Pathophysiological Overview

et al. 2022

View full text Add to dashboard Cite

show abstract

Exploring Side Effects of Sublingual Immunotherapy: A Systemic Review and Meta-Analysis

Janz,

Jimoh,

Nguyen

et al. 2024

Ear Nose Throat J

View full text Add to dashboard Cite

Objective: Sublingual immunotherapy (SLIT) has emerged as a potentially safe and convenient option for allergen immunotherapy for patients with inhalant allergy. Larger studies on the overall side effects and severe reactions anaphylaxis are still lacking. Study Design: Systematic review and meta-analysis. Setting: Author’s review was completed in the University of Texas Medical Branch. Methods: A systematic review and meta-analysis of prospective clinical trials focusing on SLIT safety published from January 1, 2001, to December 31, 2021, was conducted. Results: Twenty-six studies were included with analysis of 7827 patients, representing over 2.7 million SLIT doses. All studies focused on single-antigen immunotherapy. The mean duration of treatment was 11.54 months. Local side effects were present in 40.83% of patients [95% confidence interval (CI) 24.78-57.96]. Systemic side effects were encountered in 1.09% of SLIT patients (95% CI 0.57-1.78). Anaphylaxis was reported in 0.13% of patients (95% CI 0.06-0.22). Discontinuation rates due to side effects were low, at 4.32% of patients (95% CI 3.28-5.49). Conclusion: This meta-analysis shows that single-antigen SLIT is well-tolerated, with overall low rates of systemic side effects including anaphylaxis. Although there is a high rate of minor local side effect, the treatment attrition during the first year is low. With growing allergy burden worldwide, SLIT is a convenient and economically feasible option for immunotherapy. Further work is needed to evaluate long-term safety and efficacy of single as well as multi-antigen SLIT, including quality of life assessments.

show abstract

Outcome of Sublingual Immunotherapy in Allergic Rhinitis

Cited by 2 publications

References 16 publications

Allergic Rhinitis: A Clinical and Pathophysiological Overview

Allergic Rhinitis: A Clinical and Pathophysiological Overview

Exploring Side Effects of Sublingual Immunotherapy: A Systemic Review and Meta-Analysis

Contact Info

Product

Resources

About